SynopsisTrisenox is a chemotherapy drug and is also called Trisenox or ATO. It is a treatment for a type of acute myeloid leukaemia called acute promyelocytic leukaemia (APL). The global Trisenox market was valued at US$ 59 million in 2023 and is anticipated to.....
SynopsisArsenic trioxide is a chemotherapy drug and is also called Trisenox or ATO. It is a treatment for a type of acute myeloid leukaemia called acute promyelocytic leukaemia (APL). The global Arsenic Trioxide Drugs market was valued at US$ 59 million in 2023.....
SynopsisVesanoid is medication used for the treatment of acne and acute promyelocytic leukemia. For acne, it is applied to the skin as a cream or ointment. For leukemia, it is taken by mouth for up to three months. The global Vesanoid market was valued at US$ 27.....
SynopsisTretinoin is medication used for the treatment of acne and acute promyelocytic leukemia. For acne, it is applied to the skin as a cream or ointment. For leukemia, it is taken by mouth for up to three months. The global Tretinoin Drugs market was valued a.....
SynopsisPegademase bovine Injection is a modified enzyme used for enzyme replacement therapy for the treatment of severe combined immunodeficiency. The global Pegademase Bovine market was valued at US$ 79 million in 2023 and is anticipated to reach US$ 103.7 mil.....
SynopsisPegademase bovine Injection is a modified enzyme used for enzyme replacement therapy for the treatment of severe combined immunodeficiency. The global Pegademase Bovine Drugs market was valued at US$ 79 million in 2023 and is anticipated to reach US$ 103.....
SynopsisAdagen Injection is a modified enzyme used for enzyme replacement therapy for the treatment of severe combined immunodeficiency. The global Adagen market was valued at US$ 79 million in 2023 and is anticipated to reach US$ 103.7 million by 2030, witnessi.....
SynopsisRevcovi (elapegademase-lvlr) is a new enzyme replacement therapy indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. The global Elapegademase-lvlr Drugs market was valued at US$.....
SynopsisRevcovi is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. The global Revcovi market was valued at US$ 53 million in 2023 and is anticipated to reach US$ 70 million by 2030,.....
SynopsisAdenosine deaminase deficiency is an autosomal recessive metabolic disorder that causes immunodeficiency. It occurs in fewer than one in 100,000 live births worldwide. The global Adenosine Deaminase Deficiency market was valued at US$ 131.5 million in 20.....
